Researchers conducted a target-trial emulation to compare the effects of tirzepatide and dulaglutide on MACE risk among patients with T2D and ASCVD.

Adults aged 60 years or older with type 2 diabetes (T2D) had the lowest mortality when their interprofessional care leaned slightly towards nurses; however, care dominated by GPs was associated with ...

A recent study has found that nearly 54% of patients with type 2 diabetes (T2D) suffer from fatty pancreas disease (FPD).

Use of semaglutide and tirzepatide, compared with sitagliptin, were associated with lower risks for heart failure hospitalization and mortality in HFpEF and type 2 diabetes. Use of semaglutide and ...

Overall, 15% of patients progressed to T2D; the 5-year risk for progression to T2D was 54% for those with prediabetes A1c levels of 6.0%-6.4%, 30% for those with ...

Multiple manufacturers receive FDA approval for generic dapagliflozin to treat type 2 diabetes and lower heart failure risks in high-risk T2D patients.